Arcturus Therapeutics Holdings Inc.
ARCTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Arcturus Therapeutics Holdings Inc. (ARCT) is listed under Biotechnology. The $170.3M market capitalization puts ARCT squarely in micro-cap range for its industry. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Market Cap
$170.3M
Beta
2.36
P/E (TTM)
—
P/E (Fwd)
-1.49
EPS (TTM)
$-2.83
EPS (Fwd)
$-4.02
ROE
-37.0%
ROA
-19.1%
Cash
$211.4M
Total Debt
$24.0M
Free CF
$11.3M
52W Change
-58.8%
Annual Financials
Cash vs Debt
Where ARCT stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ARCT finished 14.73% below its 150-day moving average ($7.47) and 27.94% below its 200-day moving average ($8.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARCT overbought or oversold?
At the July 15, 2026 close, ARCT's RSI(14) was 36.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $211.4M in cash comfortably exceeding the $24.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $11.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -37.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $205.8M (2022) to $67.2M (2025), a 67% decline worth watching.
With a beta above 1.5, ARCT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ARCT.